Latest News

  • Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial Results Read More
  • FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder Read More
  • Trading in Alkermes Ordinary Shares Halted Today Read More
  • Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831 Read More


Response to Current Events